Naproxen in effervescent tablets – the influence of pharmacokinetic parameters on pharmacodynamics Review article
Article Sidebar
Published:
Dec 31, 2023
Keywords:
effervescent tablets, naproxen, NSAIDs, pharmacokinetics, pain therapy
Main Article Content
Abstract
The selection of the drug and its form is a key step preceding effective therapy. The pharmacokinetics of a drug is as important as its pharmacodynamics. Modern drug form technologies allow the manipulation of pharmacokinetic parameters at the absorption stage, which has a practical impact on the effectiveness of pain treatment. Naproxen in effervescent tablets may be a therapeutic option for those who require faster pain relief or patients at high risk of gastrointestinal bleeding.
Article Details
How to Cite
Rudnicka, M. (2023). Naproxen in effervescent tablets – the influence of pharmacokinetic parameters on pharmacodynamics. Medycyna Faktow (J EBM), 16(4(61), 378-382. https://doi.org/10.24292/01.MF.0423.14
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Hassan DS, Hasary HJ. The impact of viscosity on the dissolution of naproxen immediate release tablet. J Taibah Univ Med Sci. 2023; 18(4): 687e695.
2. Haznar D, Garbacz G. Wybrane aspekty technologii leków o modyfikowanym uwalnianiu. Farm Pol. 2009; 65(10): 749-57.
3. Moore RA, Derry S, Wiffen PJ et al. Effects of food on pharmacokinetics of immediate release oral formulations of aspirin, dipyrone, paracetamol and NSAIDs – a systematic review. Br J Clin Pharmacol. 2015; 80(3): 381-8.
4. Kashuba ADM, Bertino JS, Nafziger AN. Dosing of aminoglycosides to rapidly attain pharmacodynamic goals and hasten therapeutic response by using individualized pharmacokinetic monitoring of patients with pneumonia caused by gram-negative organisms. Antimicrob Agents Chemother. 1998; 42(7): 1842-4.
5. Kanani K, Gatoulis SC, Voelker M. Influence of Differing Analgesic Formulations of Aspirin on Pharmacokinetic Parameters. Pharmaceutics. 2015; 7: 188-98.
6. Zhou D, Zhang Q, Lu W et al. Single- and multiple-dose pharmacokinetic comparison of a sustained-release tablet and conventional tablets of naproxen in healthy volunteers. J Clin Pharmacol. 1998; 38(7): 625-9.
7. Chen C, Bujanover S, Kareht S et al. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions. Headache. 2015; 55(2): 265-75.
8. Zauška L, Benová E, Urbanová M et al. Adsorption and Release Properties of Drug Delivery System NaproxenSBA-15: Effect of Surface Polarity, Sodium/Acid Drug Form and pH. J Funct Biomater. 2022; 13: 275.
9. Samineni R, Chimakurthy J, Konidala S. Emerging role of biopharmaceutical classification and biopharmaceutical drug disposition system in dosage form development: A systematic review. Turk J Pharm Sci. 2022; 19(6): 706-13.
10. Mora CP, Martınez F. Solubility of naproxen in several organic solvents at different temperatures. Fluid Phase Equilibria. 2007; 255: 70-7.
11. Angiolillo DJ, Weisman SM. Clinical Pharmacology and Cardiovascular Safety of Naproxen. Am J Cardiovasc Drugs. 2017; 17: 97-107.
12. Scheiman JM, Hindley CE. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events. Clin Ther. 2010; 32(4): 667-77.
13. Woroń J. Dobór leków z grupy NLPZ do profilu pacjenta – na co zwrócić uwagę. Lekarz POZ. 2020; 4: 203-8.
2. Haznar D, Garbacz G. Wybrane aspekty technologii leków o modyfikowanym uwalnianiu. Farm Pol. 2009; 65(10): 749-57.
3. Moore RA, Derry S, Wiffen PJ et al. Effects of food on pharmacokinetics of immediate release oral formulations of aspirin, dipyrone, paracetamol and NSAIDs – a systematic review. Br J Clin Pharmacol. 2015; 80(3): 381-8.
4. Kashuba ADM, Bertino JS, Nafziger AN. Dosing of aminoglycosides to rapidly attain pharmacodynamic goals and hasten therapeutic response by using individualized pharmacokinetic monitoring of patients with pneumonia caused by gram-negative organisms. Antimicrob Agents Chemother. 1998; 42(7): 1842-4.
5. Kanani K, Gatoulis SC, Voelker M. Influence of Differing Analgesic Formulations of Aspirin on Pharmacokinetic Parameters. Pharmaceutics. 2015; 7: 188-98.
6. Zhou D, Zhang Q, Lu W et al. Single- and multiple-dose pharmacokinetic comparison of a sustained-release tablet and conventional tablets of naproxen in healthy volunteers. J Clin Pharmacol. 1998; 38(7): 625-9.
7. Chen C, Bujanover S, Kareht S et al. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions. Headache. 2015; 55(2): 265-75.
8. Zauška L, Benová E, Urbanová M et al. Adsorption and Release Properties of Drug Delivery System NaproxenSBA-15: Effect of Surface Polarity, Sodium/Acid Drug Form and pH. J Funct Biomater. 2022; 13: 275.
9. Samineni R, Chimakurthy J, Konidala S. Emerging role of biopharmaceutical classification and biopharmaceutical drug disposition system in dosage form development: A systematic review. Turk J Pharm Sci. 2022; 19(6): 706-13.
10. Mora CP, Martınez F. Solubility of naproxen in several organic solvents at different temperatures. Fluid Phase Equilibria. 2007; 255: 70-7.
11. Angiolillo DJ, Weisman SM. Clinical Pharmacology and Cardiovascular Safety of Naproxen. Am J Cardiovasc Drugs. 2017; 17: 97-107.
12. Scheiman JM, Hindley CE. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events. Clin Ther. 2010; 32(4): 667-77.
13. Woroń J. Dobór leków z grupy NLPZ do profilu pacjenta – na co zwrócić uwagę. Lekarz POZ. 2020; 4: 203-8.